SOPHiA GENETICS and AstraZeneca start two companion-diagnostic programmes

The multi-year collaboration covers development, validation and intended deployment of a decentralised solid-tumour companion diagnostic and a haematological-oncology programme for blood-cancer therapies. The announcement describes an approval pathway across several jurisdictions; it does not report completed validation, clearance, patient outcomes or contract value.

Impact: decentralised, standardised genomic analysis could broaden trial enrolment and treatment matching. Clinical, regulatory and laboratory quality evidence must precede care decisions.